Prelude Therapeutics Incorporated
PRLD
$1.21
-$0.03-2.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.71% | -6.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.97% | -8.52% | |||
| Operating Income | 6.97% | -2.29% | |||
| Income Before Tax | 2.66% | -11.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.66% | -11.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.66% | -11.67% | |||
| EBIT | 6.97% | -2.29% | |||
| EBITDA | 7.05% | -2.49% | |||
| EPS Basic | 2.65% | -11.49% | |||
| Normalized Basic EPS | 2.65% | -11.49% | |||
| EPS Diluted | 2.65% | -11.49% | |||
| Normalized Diluted EPS | 2.65% | -11.49% | |||
| Average Basic Shares Outstanding | 0.01% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||